Anne Wojcicki’s winning bid to reclaim control of 23andMe doesn’t necessarily end the fight over what happens to the DNA of ...

Beleaguered genetic testing company 23andMe announced Friday that it has reached an agreement to sell itself to TTAM Research ...

The California-based nonprofit founded by the former 23andMe CEO is set to close the $305 million deal in coming weeks.

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

James Moss, the director of cyber investigations at law firm Addleshaw Goddard, told Sky News the ICO's fine was "about as ...

【6月17日再生元制药拒对23andMe提新收购要约】 6月17日，再生元制药公司发言人透露，公司已拒绝为基因检测公司23andMe提出高于2.56亿美元的新收购要约。在破产拍卖中，23andMe联合创始人Anne ...

A nonprofit run by Anne Wojcicki, the cofounder and former CEO of 23andme, has agreed to buy the genetic testing company for ...

Anne Wojcicki, former chief executive of 23andMe, won a bid to acquire the genetic testing company she founded in a second ...

23andme曾于2021年高价收购远程医疗平台Lemonaid，本来业务就持续亏损，2023年还爆发近700万用户的基因数据被泄露事故，导致23andMe陷入了信任危机，集体诉讼接连不断，创始人安妮·沃西基多次提出私有化方案，意图公司重回自己手中， ...

格隆汇6月17日｜据路透，再生元制药公司发言人表示，该公司已拒绝对基因检测公司23andMe提出新的高于2.56亿美元的收购要约。在破产拍卖中，23andMe公司联合创始人Anne Wojcicki控制的一家非营利组织提出的3.05亿美元报价超过了再生元的出价，这意味着Wojcicki将重新获得对23andMe的控制权。

Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of the DNA-testing company she co-founded.

Anne Wojcicki is taking back reins of 23andMe after outbidding Regeneron. The entrepreneur's proposal offers better ...